

Amendments to the Claims:

1. to 28. (Cancelled)

29. (Currently amended) A method of immunizing a host ~~against infection caused by a strain of *Chlamydia*~~, which comprises:

administering to the host an ~~immunoeffective amount of an~~ attenuated bacteria harbouring a vector comprising a nucleic acid molecule encoding at least one immunoprotection-inducing *Chlamydia* protein or a fragment thereof which generates a *Chlamydia* protein specific immune response and a promoter operatively coupled to said nucleic acid molecule for expression of said *Chlamydia* protein or fragment thereof in cells of the host but not in said attenuated bacteria.

30. (Original) The method of claim 29 wherein said immunoprotection inducing *Chlamydia* protein or fragment thereof is a major outer membrane protein (MOMP) of a strain of *Chlamydia*.

31. (Original) The method of claim 30 wherein said strain of *Chlamydia* is a strain of *Chlamydia pneumoniae*.

32. (Original) The method of claim 30 wherein said strain of *Chlamydia* is a strain of *Chlamydia trachomatis*.

33. (Cancelled)

34. (Currently amended) The method of claim 29 ~~33~~ wherein said promoter is a cytomegalovirus promoter.

35. (Currently amended) The method of claim 29 ~~33~~ wherein said vector is a plasmid vector.

36. (Currently amended) The method of claim 35 wherein said plasmid vector is ~~has the identifying characteristics of~~ pcDNA3/MOMP as seen in Figure 5.

37. (Original) The method of claim 29 wherein said attenuated bacteria is an attenuated strain of *Salmonella*.

38. (Original) The method of claim 37 wherein said attenuated strain of *Salmonella* is an attenuated strain of *Salmonella typhimurium*.

39. (Original) The method of claim 29 wherein said administration is effected to mucosal surfaces.

40. (Original) The method of claim 39 wherein said administration is effected by intranasal administration.